Profluent
|
Published 
Apr 28, 2026

Profluent Announces Strategic Partnership with Eli Lilly to Develop AI-Designed Recombinases for Genetic Medicine

XX min read

TL;DR

●     Collaboration combines Profluent'sfrontier AI platform with Lilly's leading capabilities in genetic medicines

●     AI-designed recombinases aim tounlock kilobase-scale DNA editing capabilities across multiple diseases withsevere unmet needs

‍

Read the full press here release for more.

Sign up for updates on our journey

Oops! Something went wrong while submitting the form.
|
Published 
Apr 28, 2026

More media

All Media